SMLR Quote, Financials, Valuation and Earnings

ClearPoint Neuro has a net margin of -732.34% compared to Semler Scientific's net margin of -71.02%. Semler Scientific's return on equity of -23.56% beat ClearPoint Neuro's return on equity of -73.69%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 131.57%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 136.83%. Given that ClearPoint Neuro has higher upside potential than Semler Scientific, analysts believe ClearPoint Neuro is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.296%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than ClearPoint Neuro quarterly revenues of $8.5M. Semler Scientific's net income of -$64.7M is lower than ClearPoint Neuro's net income of -$6M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.25x versus 10.48x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -732.34% compared to Semler Scientific's net margin of -2201.34%. Semler Scientific's return on equity of -23.56% beat VolitionRX's return on equity of --.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 131.57%. On the other hand VolitionRX has an analysts' consensus of $2.94 which suggests that it could grow by 344.78%. Given that VolitionRX has higher upside potential than Semler Scientific, analysts believe VolitionRX is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison VolitionRX has a beta of 1.198, suggesting its more volatile than the S&P 500 by 19.798%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than VolitionRX quarterly revenues of $246.4K. Semler Scientific's net income of -$64.7M is lower than VolitionRX's net income of -$5.4M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.25x versus 45.56x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -732.34% compared to Semler Scientific's net margin of -2828.67%. Semler Scientific's return on equity of -23.56% beat Catheter Precision's return on equity of -137.84%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 131.57%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 747.46%. Given that Catheter Precision has higher upside potential than Semler Scientific, analysts believe Catheter Precision is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.724, suggesting its less volatile than the S&P 500 by 172.434%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than Catheter Precision quarterly revenues of $143K. Semler Scientific's net income of -$64.7M is lower than Catheter Precision's net income of -$4M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.25x versus 2.71x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -732.34% compared to Semler Scientific's net margin of 0.18%. Semler Scientific's return on equity of -23.56% beat Xtant Medical Holdings's return on equity of -26.62%.

Semler Scientific has a consensus price target of $98.00, signalling upside risk potential of 131.57%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 169.02%. Given that Xtant Medical Holdings has higher upside potential than Semler Scientific, analysts believe Xtant Medical Holdings is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.392, which suggesting that the stock is 39.164% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.139, suggesting its less volatile than the S&P 500 by 113.918%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Semler Scientific's net income of -$64.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.25x versus 0.73x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.